#바이오스펙테이터 #전일(10/29, THU) #전체기사
▶ [ESMO] AZ, 방광암 '임핀지+파드셉' 3상 성공.."新이슈 촉발"
https://www.biospectator.com/news/view/30220
▶ [ESMO] 지아이이노, 'CD80/IL-2v' SC제형 1상 "ESMO IO 발표"
https://www.biospectator.com/news/view/30229
▶ [ESMO] BMS-바이오엔텍, 'PD-L1xVEGF' 폐암 2상 "잠재력”
https://www.biospectator.com/news/view/30200
▶ SK바사, IAVI·힐레만硏와 美지원 '에볼라백신' 개발협력
https://www.biospectator.com/news/view/30233
▶ ‘KRAS 변이’ 치료제 “개발한계와 앞으로 방향 4가지는?”
https://www.biospectator.com/news/view/30098
▶ [ESMO] 릴리, 'FRα ADC' 백금민감성 난소암 1상 "ORR 79%"
https://www.biospectator.com/news/view/30226
▶ [ESMO] GSK, B7-H3 ADC '약물없는' 골육종 3상 "PFS 67%↑"
https://www.biospectator.com/news/view/30221
#바이오스펙테이터 #전일(10/29, THU) #전체기사